Literature DB >> 7906583

In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.

R Silvestrini1, N Zaffaroni, L Orlandi, S Oriana.   

Abstract

The activity of Taxol and Taxotere was evaluated on three established cell lines and 19 primary cultures of human ovarian cancers and compared with that of cisplatin and doxorubicin. The cytotoxic activity of the different drugs was assessed with a clonogenic assay in cell lines and with a proliferative assay (based on [3H]thymidine [3H-dT] incorporation of cells grown in double-layer agarose for four days) in primary tumor cultures. The two assays run in parallel on the OVCA432 cell line provided similar ranking of activity for all the drugs. Taxotere was more cytotoxic than Taxol in two cell lines and showed the same degree of activity in one cell line. Moreover, the two drugs were more cytotoxic than cisplatin and doxorubicin in all cell lines. In primary cultures both Taxol and Taxotere were less active than cisplatin and doxorubicin. An activity by at least one of these two compounds was seen in 9 of 19 cases. Taxol was more frequently active than Taxotere and generally more potent. A direct relationship was observed between the proliferative activity of the tumor cell population and response to Taxol and/or Taxotere. In fact, cell lines that were highly sensitive to Taxol and Taxotere displayed 3H-dT labeling index (LI) values much higher than those observed in primary cultures (39% to 45% versus 0.2% to 12.6%). Again, primary cultures sensitive to Taxol and/or Taxotere were characterized by a median 3H-dT LI value about three times higher than that observed in resistant cultures (8.0% versus 2.6%).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7906583     DOI: 10.1002/stem.5530110622

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  4 in total

1.  Drug-eluting stents.

Authors:  Xiaodong Ma; Tim Wu; Michael P Robich; Xingwei Wang; Hao Wu; Bryan Buchholz; Stephen McCarthy
Journal:  Int J Clin Exp Med       Date:  2010-07-15

Review 2.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

3.  In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.

Authors:  W Zoli; A Flamigni; G L Frassineti; P Bajorko; F De Paola; C Milandri; D Amadori; A Gasperi-Campani
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

4.  Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells.

Authors:  N Zaffaroni; R Silvestrini; L Orlandi; A Bearzatto; D Gornati; R Villa
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.